PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...
Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings. Welcome to the PDS Biotechnology Corporation’s Third Quarter 2025 Earnings Conference Call. At this time, all participants are ...
Summary of GST provisions on detention of goods and vehicles, e-way bill compliance, penalty, appeal, and refund procedures under Sections 68 and ...
Not only are stock market valuations stretched, but on the metrics that are most reliable for predicting future returns, the U.S. market is at an all-time high. We can say that factually and therefore ...
PDS Biotechnology ( ($PDSB) ) just unveiled an update. On November 11, 2025, PDS Biotechnology Corporation announced a securities purchase ...
EAST PRINCETON, N.J. (AP) — EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Thursday reported a loss of $9 million in its third quarter. The East Princeton, New Jersey-based ...
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback